MBX Biosciences, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $31.0M | — | $18.5M | — | — | — | $19.3M |
| SG&A Expense | — | $9.9M | — | $8.8M | — | — | — | $4.7M |
| Operating Income | — | $-40.9M | — | $-27.3M | — | — | — | $-23.9M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-37.1M | — | $-23.5M | — | — | — | $-21.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.78 | — | $-0.50 | — | — | — | $-0.21 |
| EPS (Diluted) | — | $-0.78 | — | $-0.50 | — | — | — | $-0.21 |
| Shares Outstanding (Basic) | 48.2M | 47.7M | 47.6M | 46.6M | 47.5M | 44.9M | 134.7M | 102.6M |
| Shares Outstanding (Diluted) | 48.2M | 47.7M | 47.6M | 46.6M | 47.5M | 44.9M | 134.7M | 102.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |